BioNTech SE (NASDAQ:BNTX) was down sharply on Tuesday after issuing weaker‑than‑expected 2026 revenue guidance as Covid vaccine sales normalize and outlining a capital‑intensive pivot toward oncology.
- BNTX stock is sinking. See the chart and price action here.
The company’s co-founders Ugur Sahin and Ozlem Tureci plan to transition out by the end of 2026 to launch a new mRNA‑focused firm, creating a combination that is pressuring near‑term earnings expectations and unsettling some investors about the transition phase.
Covid Vaccine Sales Down
The company guided 2026 total revenue to roughly $2.2–$2.5 billion, below Street expectations, stating that Covid will be a smaller contributor going forward and growth will depend increasingly on the oncology pipeline.
CFO Ramon Zapata emphasized on the earnings call that “for COVID-19, we continue to see a stable position with a strong market share and stable pricing,” but also that “we have always assumed lower volumes versus last year,” framing the business as performing “within our expectations for the year” rather than returning to pandemic‑era windfalls.
Oncology Pivot
BioNTech will lean into its long‑term oncology portfolio with CEO Sahin saying, “Simply put, we are transforming scientific advances into late-stage programs in our priority oncology program across indications.”
“We are building the capabilities and the financial strength to translate positive data rapidly into market opportunities and most importantly, into patient benefit,” the CEO added, reinforcing the narrative that investors must bridge a multi‑year investment phase before seeing substantial oncology revenue contribution.
At the same time, BioNTech has been at pains to reassure investors on balance‑sheet strength and funding for the oncology strategy.
“With these launches in major markets and with a strong balance sheet, over EUR 16 billion in total cash, equivalents and securities, we have the resources and the flexibility to fund the oncology transition, while maintaining a disciplined P&L,” Sahin told analysts and investors.
That cash position—about $17.2 billion—supports planned R&D spending in the $2.4–2.7 billion range as the company invests in pumitamig and its mRNA cancer immunotherapies.
BNTX Bulls Retreat
Investors don’t seem to be comfortable with so many changes at once. The departure of Sahin and Tureci raises questions about leadership continuity and whether core scientific and strategic talent will be spread across two entities.
Together, the softer‑than‑hoped revenue outlook, visible Covid normalization, stepped‑up R&D investment and looming founder transition are contributing to Tuesday’s BioNTech stock wipe-out.
BNTX Price Action: According to data from Benzinga Pro, BioNTech shares were down 17.67% at $84.11 at the time of publication Tuesday.
Photo: Piotr Swat / Shutterstock
Recent Comments